Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy
Author:
Affiliation:
1. Department of Nephrology, the Second Affiliated Hospital of Nanchang University, Nanchang, China;
2. Department of Nephrology, People's Hospital of Xinyu City, Xinyu, China
Publisher
Informa UK Limited
Subject
Nephrology,Critical Care and Intensive Care Medicine,General Medicine
Link
https://www.tandfonline.com/doi/pdf/10.1080/0886022X.2019.1637758
Reference21 articles.
1. Glomerular Diseases: Membranous Nephropathy—A Modern View
2. KDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis
3. A randomized study comparing methylprednisolone plus chlorambucil versus methylprednisolone plus cyclophosphamide in idiopathic membranous nephropathy.
4. Long-Term Outcomes in Idiopathic Membranous Nephropathy Using a Restrictive Treatment Strategy
5. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy11See Editorial by Cattran, p. 349.
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Effect of cyclophosphamide combined with glucocorticoid therapy on idiopathic membranous nephropathy: A multicenter open-label randomized controlled trial;Clinical Nephrology;2024-07-01
2. Meta-analysis of the effects of CYP3A5*3 gene polymorphisms on tacrolimus blood concentration and effectiveness in Chinese patients with membranous nephropathy;Frontiers in Pharmacology;2024-05-21
3. Efficacy of rituximab, tacrolimus and cyclophosphamide in the treatment of idiopathic membranous nephropathy and its influencing factors: Retrospective cohort study;2024-04-25
4. Comparison of the efficacy of steroid-free versus classic steroid-containing regimens in primary membranous nephropathy;Frontiers in Pharmacology;2024-02-14
5. Comparative pharmacoeconomic analysis of rituximab and traditional tacrolimus regimens in membranous nephropathy in China;Frontiers in Pharmacology;2024-01-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3